信迪利单抗联合贝伐珠单抗治疗晚期NSCLC患者的临床疗效及对患者肿瘤标志物水平的影响

doi:10.3969/j.issn.1671-7171.2025.09.014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1236 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨信迪利单抗联合贝伐珠单抗治疗晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的临床疗效及对患者肿瘤标志物水平的影响。【方法】选取2018年1月至2022年10月在本院接受治疗的86例晚期NSCLC患者,根据治疗方案不同将患者分为对照组(接受贝伐珠单抗治疗,n=38)和观察组(在对照组基础上联合信迪利单抗治疗,n=48)。比较两组疗效、肿瘤标志物水平、免疫功能指标、生活质量评分、不良反应发生情况及生存情况。【结果】治疗后,观察组总缓解率和疾病控制率均高于对照组(P<0.05)。治疗后,观察组肿瘤标志物癌胚抗原(CEA)、细胞角蛋白19片段21-1(CYFRA21-1)、糖类抗原50(CA50)、糖类抗原125(CA125)、鳞状细胞癌相关抗原(SCCAg)水平均低于对照组(P<0.05);外周血中CD3⁺、CD4⁺及CD4⁺/CD8⁺均高于对照组(P<0.05),CD8⁺低于对照组(P<0.05)。观察组生活质量各项评分均高于对照组(P<0.05)。治疗期间,两组不良反应发生率比较,差异均无统计学意义(P>0.05)。随访1年期间,观察组存活率为72.92％,高于对照组的47.37％(P<0.05)。【结论】信迪利单抗联合贝伐珠单抗治疗晚期NSCLC患者,可显著提高总缓解率和疾病控制率,降低肿瘤标志物水平,改善患者免疫功能和生活质量,且安全性良好,提高存活率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	石常乐
	秦鸿
	储意青

关键词 ：癌, 非小细胞肺, 生物标记, 肿瘤, 治疗结果

Abstract：【Objective】 To explore the clinical efficacy of Sintilimab combined with bevacizumab in the treatment of patients with advanced non-small cell lung cancer(NSCLC) and its impact on the levels of tumor markers in patients.【Methods】 A total of 86 patients with advanced NSCLC treated in our hospital from January 2018 to October 2022 were selected. According to different treatment regimens, the patients were divided into the control group(treated with bevacizumab alone, n=38) and the observation group(treated with Sintilimab combined with bevacizumab on the basis of the control group, n=48). The efficacy, tumor marker levels, immune function indicators, quality of life scores, adverse reactions and survival status were compared between the two groups.【Results】 After treatment, the overall response rate(ORR) and disease control rate(DCR) of the observation group were higher than those of the control group(P<0.05). After treatment, the levels of tumor markers [carcinoembryonic antigen(CEA), cytokeratin 19 fragment 21-1(CYFRA21-1), carbohydrate antigen 50(CA50), carbohydrate antigen 125(CA125), squamous cell carcinoma-associated antigen(SCCAg)] in the observation group were lower than those in the control group(P<0.05); the percentages of CD3⁺, CD4⁺ and the ratio of CD4⁺/CD8⁺ in peripheral blood of the observation group were higher than those in the control group(P<0.05), while the percentage of CD8⁺ was lower than that in the control group(P<0.05). All quality of life scores of the observation group were higher than those of the control group(P<0.05). During the treatment period, there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). During the 1-year follow-up, the survival rate of the observation group was 72.92%, which was higher than 47.37% of the control group(P<0.05).【Conclusion】 Sintilimab combined with bevacizumab in the treatment of patients with advanced NSCLC can significantly improve the ORR and DCR, reduce the levels of tumor markers, improve the immune function and quality of life of patients, with good safety and increased survival rate.

Key words： Carcinoma, Non-Small-Cell Lung Biomarkers, Tumor Treatment Outcome

收稿日期: 2025-03-31

中图分类号:

R734.2

通讯作者: ^*E-mail:CYQ18791995636@163.com

引用本文:

石常乐, 秦鸿, 储意青. 信迪利单抗联合贝伐珠单抗治疗晚期NSCLC患者的临床疗效及对患者肿瘤标志物水平的影响[J]. 医学临床研究, 2025, 42(9): 1538-1541.
SHI Changle, QIN Hong, CHU Yiqing. Clinical Efficacy of Sintilimab Combined with Bevacizumab in the Treatment of Patients with Advanced NSCLC and its Impact on Tumor Marker Levels. JOURNAL OF CLINICAL RESEARCH, 2025, 42(9): 1538-1541.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.09.014 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I9/1538

[1] 王朝,韩雪,张爱霞. LIPI评分对PD-1/PD-L1抑制剂治疗非小细胞肺癌效果与预后的价值分析[J].中国现代医学杂志,2023,33(6):55-60.
[2] 杨光霞,程云涛,刘琳琳,等. 阿美替尼片联合贝伐珠单抗注射液治疗表皮生长因子受体突变的晚期非小细胞肺癌患者的临床研究[J].中国临床药理学杂志,2023,39(11):1528-1532.
[3] ZHOU Q, XU C R, CHENG Y, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC(ARTEMIS-CTONG1509):a multicenter phase 3 study[J].Cancer Cell,2021, 39(9):1279-1291.
[4] 张龙志,山长婷,徐静,等. 信迪利单抗和贝伐珠单抗联合治疗肺腺癌致免疫性输尿管炎/膀胱炎1例报告及文献复习[J].中国肿瘤生物治疗杂志,2023,30(6):533-537.
[5] YANG Y P, ZHOU H, ZHANG L. Response to Letter to the Editor:efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC:a randomized, double-blind, phase 3 study(ORIENT-11)[J].J Thorac Oncol,2020, 15(12):e191-e192.
[6] 周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2003:202-203.
[7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准:RECIST[J].循证医学,2004,4(2):85-90.
[8] 潘雁,徐云华,王韡旻,等. FACT-L中文版4.0用于肺癌化疗患者生命质量测定的分析研究[J].中国卫生资源,2010,13(6):265-267.
[9] 王雷,李婧怡,李幸,等. 晚期非小细胞肺癌免疫检查点抑制剂治疗专家共识解读[J].河北医科大学学报,2020,41(1):1-6.
[10] GARCIA J, HURWITZ H I, SANDLER A B, et al. Bevacizumab(Avastin^®) in cancer treatment:A review of 15 years of clinical experience and future outlook[J].Cancer Treat Rev,2020, 86:102017.
[11] ZHANG L, MAI W Q, JIANG W Y, et al. Sintilimab:a promising anti-tumor PD-1 antibody[J].Front Oncol,2020, 10:594558.
[12] BES-SCARTEZINI F, JUNIOR R S. Prognostic assessment of tumor markers in lung carcinomas[J].Rev Assoc Med Bras,2022, 68(3):313-317.
[13] YOSHIMURA A, UCHINO J, HASEGAWA K, et al. Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer[J].Transl Lung Cancer Res,2019, 8(3):227-234.
[14] LI P, QIN P, FU X M, et al. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor[J].Ann Palliate Med,2021, 10(3):3039-3049.